- ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR
-
The present invention relates to compounds of formula I shown below: wherein R0, R1, R2, R3 and A are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or conditions in which adenosine A2a receptor activity is implicated, such as, for example, cancer.
- -
-
Paragraph 001005-001007
(2021/11/13)
-
- BENZENE SULFONAMIDES AS CCR9 INHIBITORS
-
The present invention relates to compounds useful as CCR9 modulators, to compositions containing them, to methods of making them, and to methods of using them. In particular, the present invention relates to compounds capable of modulating the function of the CCR9 receptor by acting as partial agonists, antagonists or inverse agonists. Such compounds may be useful to treat, prevent or ameliorate a disease or condition associated with CCR9 activation, including inflammatory and immune disorder diseases or conditions such as inflammatory bowel diseases (IBD).
- -
-
Page/Page column 88; 89
(2015/07/15)
-